Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etavopivat - Forma therapeutics

Next Previous
Drug Profile

Etavopivat - Forma therapeutics

Alternative Names: FT-4202; NN 7535; NN-7536; NN7535 – Etavopivat in SCD; NN7535 – Etavopivat in Sickle cell disease; NN7536 – Etavopivat in Beta thalassemia

Latest Information Update: 06 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FORMA Therapeutics
  • Class 2 ring heterocyclic compounds; Antianaemics; Benzene derivatives; Dioxanes; Ketones; Propanols; Pyridines; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Pyruvate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia; Thalassaemia
  • Phase II Myelodysplastic syndromes

Most Recent Events

  • 06 Dec 2025 Preliminary efficacy and adverse events data from a phase I/II HIBISCUS KIDS trial in sickle cell anaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 24 Sep 2025 Forma Therapeutics completes a phase-II clinical trials in Thalassaemia (In adolescents, In adults) in the US, Canada, Egypt, Lebanon and United Kingdom (PO) (NCT04987489)
  • 12 Sep 2025 Novo Nordisk completes phase I clinical trials in Sickle cell anaemia (In adults) in USA (PO) (NCT07023029)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top